Penile Cancer Staging: How TNM Categories Work

Penile cancer staging uses the TNM system to classify how far the disease has spread, and it is the single strongest factor in predicting survival and deciding treatment. The system grades three dimensions: how deep the primary tumor has invaded (T), whether cancer has reached nearby lymph nodes (N), and whether it has spread to distant organs (M). The most current framework is the 8th edition of the American Joint Committee on Cancer (AJCC) staging system, which made meaningful changes to earlier versions and now separates survival groups more clearly than before. Because penile cancer is rare in high-income countries, staging decisions often rest on limited data compared with more common cancers, and the accuracy of each staging tool matters a great deal.

How the T Category Works

The T category describes how deeply the tumor has grown into the structures of the penis. The penis contains several distinct tissue layers, and each layer the cancer invades corresponds to a higher T stage. At the lowest end, Tis (carcinoma in situ) and Ta represent cancer confined to the surface epithelium. T1 indicates invasion through the basement membrane into subepithelial tissue, and the 8th edition subdivides T1 into T1a (no lymphovascular invasion and not high grade) and T1b (with lymphovascular invasion or high grade). These subdivisions matter because they change how aggressively the groin lymph nodes need to be evaluated.

The most consequential change in the 8th edition was how it handles deeper invasion. Older editions lumped invasion of both the corpus spongiosum and the corpora cavernosa together as T2. The current system now classifies invasion of the corpus spongiosum alone as T2 and invasion of the corpora cavernosa as T3. This distinction reflects a real difference in outcomes: in one single-center study, the five-year overall survival for T2 versus T3 under the 8th edition was 91% and about 50%, a statistically significant gap.¹ T4, the highest local stage, involves invasion into adjacent structures such as the pubic bone or prostate.

There is ongoing debate about whether even the 8th edition T categories carve risk finely enough. Modified staging proposals have tried to further subdivide T2 and T3 based on combinations of urethral invasion and specific anatomical structures, and some have shown sharper survival separation in retrospective analyses.² None of these alternatives has yet been adopted into official guidelines, but they signal that the current system still has room for improvement.

Why Lymph Node Status Matters So Much

If there is one staging element that carries the most weight for long-term survival in penile cancer, it is the N category. Whether the cancer has spread to the inguinal (groin) lymph nodes, and if so, to how many and on which side, is the strongest single predictor of disease-specific death. The 8th edition improved on earlier versions by better separating N1 (a single positive node without extranodal extension) from N2 (multiple or bilateral positive nodes, or extranodal extension) and N3 (pelvic node involvement or fixed inguinal masses). A study comparing the 7th and 8th editions found that the 8th N category better separated survival between pN1 and pN2, and reclassified about 15% of node-positive cases into pN1, a group with roughly 64% five-year overall survival.³

Even within the current N2 category, researchers have found that patients are not all alike. A study of patients staged under the 7th edition showed that splitting N2 into unilateral versus bilateral inguinal involvement revealed a survival difference. The three-year disease-specific survival rates for N1, N2, and N3 were roughly 90%, 66%, and 34% under the 7th edition system, with the proposed modification producing slightly different but similarly separated figures of about 91%, 61%, and 31%.⁴ The overall pattern is clear: once cancer reaches the groin nodes, survival drops substantially, and it drops again with each step up in node burden.

Imaging for Local Staging

Clinical staging of the primary tumor starts with physical examination, but physical exam alone has limited accuracy. In one study, clinical staging matched the final pathological stage in only about half of patients, with 20% upstaged and 28% downstaged after surgery.⁵ That means relying on hands and eyes alone leads to the wrong stage classification nearly half the time, which can affect treatment planning.

MRI is the most studied imaging tool for local T staging. One study reported a good correlation between MRI findings and surgical pathology, with stage-specific sensitivities and specificities of 85% and 83% for T1, 75% and 89% for T2, and 88% and 98% for T3. MRI was especially reliable for detecting invasion of the corpora cavernosa.⁶ A technique involving pharmacologically induced erection during MRI (using prostaglandin injection) was initially thought to improve accuracy by distending the penile tissues. However, a systematic review and meta-analysis found that MRI with and without artificial erection showed similar diagnostic accuracy, with comparable sensitivity and specificity.⁷ This is good news for patients, since the injection adds discomfort and complexity to an already unpleasant process.

Ultrasound also has a role. It is sometimes used to assess the depth of tumor invasion and to evaluate inguinal lymph nodes, particularly when combined with fine-needle aspiration of suspicious nodes. Penile cancer staging relies more heavily on clinical nodal assessment of the inguinal lymph node chains than many other cancers do, and ultrasound fits into that workflow as a relatively accessible bedside tool.⁸

Sentinel Lymph Node Biopsy

One of the hardest decisions in penile cancer management is what to do about inguinal lymph nodes that feel normal on physical exam. Up to a quarter of patients with clinically normal groins turn out to have microscopic cancer in the nodes, while many patients with enlarged nodes turn out to have only reactive inflammation. The full surgical removal of all inguinal lymph nodes (inguinal lymphadenectomy) carries serious side effects, including lymphedema, wound breakdown, and prolonged recovery. This created a push for less invasive ways to check the nodes.

Dynamic sentinel lymph node biopsy (DSNB) identifies and removes only the first node or nodes that drain the tumor site. A meta-analysis pooling data from 28 studies and nearly 2,900 patients found that DSNB had a pooled sensitivity of about 87%.⁹ Individual center results vary; one study reported sensitivity of 79% with a negative predictive value of 97%, meaning a negative biopsy was highly reassuring but not perfect.¹⁰

The catch is that DSNB works best in patients whose groin nodes are clinically normal (cN0). In patients with palpable inguinal nodes, the false-negative rate climbs because large tumor deposits can block lymphatic drainage and redirect the tracer away from the actual metastatic node. One study of patients with palpable nodes found that DSNB missed cancer in about 13% of patients, a rate the authors considered too high to replace complete lymphadenectomy in that group.¹¹ Guidelines currently recommend DSNB at specialized centers for intermediate- and high-risk patients with clinically negative groins, while patients with palpable or biopsy-proven positive nodes should proceed to full inguinal lymphadenectomy.¹²

Detecting Distant Spread

The M category asks whether cancer has reached organs beyond the regional lymph nodes, most commonly the lungs, liver, or bone. CT of the chest, abdomen, and pelvis is the standard first-line tool for checking distant spread. PET/CT, which uses a radioactive glucose tracer to light up metabolically active tumor deposits, has a more specialized role.

PET/CT is most useful when inguinal node metastases have already been confirmed and the question is whether cancer has extended into the pelvic nodes or beyond. One study found that PET/CT had 91% sensitivity, 100% specificity, and 96% overall diagnostic accuracy for detecting pelvic nodal involvement in patients with inguinal node-positive disease, and also picked up distant metastases in five patients that might otherwise have been missed.¹³ For patients without proven inguinal metastases, though, PET/CT adds less value. The evidence base overall remains thin, and a review noted that the role of PET/CT in penile cancer is still unsettled, though it appears particularly useful before planned systemic chemotherapy or extensive surgery to confirm that distant disease is not already present.¹⁴

How Stage Translates to Survival

Combining the T, N, and M categories produces an overall anatomic stage group that maps to survival in a stepwise fashion. A large multicenter study reported five-year disease-specific survival rates across the 8th edition stage groups: stages 0 and I had survival near 100%, stage IIA was around 86%, stage IIB about 81%, stage IIIA roughly 66%, stage IIIB dropped to 34%, and stage IV was 23%.¹⁵ The biggest survival cliffs appear at the boundary between stage II and stage III, which is where lymph node involvement enters the picture, and again between IIIA and IIIB.

One subtlety worth flagging: the survival gap between IIA and IIB did not reach statistical significance in that study, which suggests the current system may not perfectly separate those two groups. Refining the staging system is an active area of research, with investigators looking at whether adding information like HPV status or specific histological features could sharpen the prognostic separation. The 8th edition already improved on the 7th, achieving a higher discriminative ability overall.¹⁶

How Stage Drives Treatment Decisions

Staging does not exist in the abstract. It directly determines what treatment options are on the table, and the differences between adjacent stages can mean the difference between preserving the penis and losing it.

For the primary tumor, organ-sparing approaches are well-established for lower-stage disease. Techniques ranging from topical chemotherapy and laser ablation to glans resurfacing and glansectomy are appropriate for tumors up through T2 in many cases.¹⁷ The goal of organ preservation is to maintain urinary and sexual function while still achieving clear surgical margins. For T3 and T4 tumors, partial or total penectomy is more often necessary because the cancer has grown into structures that cannot be safely resected with tissue-sparing techniques.

For lymph node management, the staging of both the primary tumor and the clinical nodal status guide the approach. Patients with very low-risk primary tumors (Tis, Ta, or T1a) and no palpable groin nodes can often be observed with close follow-up rather than undergoing immediate surgery. For intermediate-risk and higher tumors with clinically negative groins, either a modified inguinal lymphadenectomy or DSNB at a specialized center is recommended. Once inguinal node metastases are confirmed by biopsy or surgery, radical inguinal lymphadenectomy on the affected side is the standard, and ipsilateral pelvic lymphadenectomy is added when multiple inguinal nodes are positive or extranodal extension is present.¹⁸

Surveillance After Treatment

Staging also shapes the follow-up schedule. Recurrence patterns differ by initial stage, so the intensity and duration of surveillance are tailored accordingly. Physical examination of the penis and both groins remains the most important surveillance tool at every stage.¹⁹ For patients who underwent sentinel node biopsy rather than full lymphadenectomy, periodic ultrasound of the inguinal regions is often added to catch early recurrence in the nodes that were left in place. Patients who had radical inguinal lymphadenectomy for node-positive disease generally undergo regular CT scanning of the pelvis and abdomen, since pelvic recurrence and distant spread are the main concerns in this higher-risk group.²⁰

How long to keep surveilling is an open question. Most recurrences happen within the first two years, but late recurrences do occur. Current European guidelines recommend follow-up for at least five years, with more frequent visits in the first two years and gradually extending intervals after that. Patients treated with organ-sparing approaches need closer monitoring of the local site, since local recurrence rates are higher than after partial penectomy, though local recurrences caught early can usually be treated again with organ-sparing methods.

Staging Challenges with Non-Squamous Subtypes

About 95% of penile cancers are squamous cell carcinomas, and the entire TNM staging system was built around that histology. The remaining 5% include melanoma, sarcoma, lymphoma, and metastases from other primary sites.²¹ These rare subtypes behave differently and do not fit neatly into the standard penile cancer staging framework.

Penile melanoma illustrates the problem well. A study of over 100 cases found that overall survival was significantly worse with lymph node or distant metastasis and with greater depth of invasion, as you would expect. But the survival curves for T2 and T3 were not clearly separated, leading the authors to propose an alternative system that expands the T2 category for penile melanoma specifically.²² This finding highlights something broader: a staging system designed for the most common histology may produce misleading prognostic information when applied to a biologically different tumor type. Clinicians managing non-squamous penile cancers often draw on staging frameworks from the corresponding tumor type elsewhere in the body, such as cutaneous melanoma staging criteria for penile melanoma, while adapting for the anatomical differences of the penis.

The HPV Question and Future Staging Refinements

About a third of penile squamous cell carcinomas are linked to human papillomavirus (HPV) infection, and there is growing interest in whether HPV-positive tumors behave differently enough to warrant separate staging or at least an adjustment in prognosis. Preliminary work has suggested that HPV status or p16 expression (a surrogate marker for HPV-driven tumors) could add prognostic information beyond what the TNM system provides.²³ In head and neck cancer, HPV-positive tumors have their own distinct staging system because they have markedly better outcomes. Whether penile cancer will eventually follow the same path remains to be seen. The evidence is not yet strong enough to support routine changes in staging based on HPV status, but it is a space to watch.

Other molecular and histological features are also under investigation. Lymphovascular invasion and perineural invasion are already recognized as predictors of lymph node metastasis within the current system, but they do not formally change the stage assignment itself. Some researchers have proposed incorporating these features more formally into risk stratification, which could shift how aggressive the lymph node workup needs to be for a given T stage. Pathological grading also remains important but imperfect; variability between pathologists in assessing tumor grade and subtype has been documented, which can cascade into different staging and treatment recommendations for the same patient depending on who reads the slides.²⁴ Centralized pathology review at specialized centers is one practical response to this problem, and it is recommended by current European guidelines for exactly this reason.